Immuron provided a company update for the first half of 2016. Key developments included reaching 50% recruitment milestones in its Phase 2 NASH trial, initiating a pediatric NASH study, and reporting highly successful pre-clinical data for IMM-529 in treating C. difficile that demonstrated efficacy without antibiotics. The company also started pre-clinical programs in colitis and collaborated with the US Army on a Shigella vaccine. In its OTC business, Immuron expanded its US customer and retail footprint and launched products in China through an e-commerce partnership. Upcoming milestones include reporting interim NASH results in 4Q2016 and initiating the Phase 1 C. difficile trial.

1. COMPANY UPDATE
July 2016

2. Forward-Looking Statement
Certain statements made in this presentation are forward-looking statements and are based on
Immuron’s current expectations, estimates and projections. Words such as “anticipates,” “expects,”
“intends,” “plans,” “believes,” “seeks,” “estimates,” “guidance” and similar expressions are intended to
identify forward-looking statements.
Although Immuron believes the forward-looking statements are based on reasonable assumptions,
they are subject to certain risks and uncertainties, some of which are beyond Immuron’s control,
including those risks or uncertainties inherent in the process of both developing and commercializing
technology. As a result, actual results could materially differ from those expressed or forecasted in
the forward-looking statements.
The forward-looking statements made in this presentation relate only to events as of the date on
which the statements are made. Immuron will not undertake any obligation to release publicly any
revisions or updates to these forward-looking statements to reflect events, circumstances or
unanticipated events occurring after the date of this presentation except as required by law or by any
appropriate regulatory authority.
2

3. Immuron Limited
1H 2016 Developments
3
Company Overview and Pipeline
1H 2016 Developments
Upcoming Milestones
Summary

4. Immuron Limited
Introduction
4
• Clinical stage biopharmaceutical company focused on oral immunotherapies for
the treatment of inflammatory and gut mediated diseases
• Strong platform technology (dairy-derived antibodies); wide applicability/low cost
- Validations: Product approved and launched; US NIH fully funding Phase II studies (ASH)
• Lead asset IMM-124E targeting fatty liver diseases (NASH / ASH)
- Targeting LPS endotoxins, a key disease mediator, and up-regulation of suppressor T-Cells
- Early studies have shown evidence of anti-inflammatory effects + prevention of fibrosis
- Potential exist to expand the use of IMM-124E in other indications such as diabetes
• NASH represents a blockbuster opportunity. Large and growing market ($35B-$40B
by 2030) driven by obesity epidemic. No approved drugs. High BD activity
• Second key asset is IMM-529 which is targeting C-Difficile. This is a bacterial
infection for which Immuron could get orphan drug designation from the FDA
• Generating growing revenues from OTC products (FY2015: $1.1M)
• Experienced management team and strong support from KOLs

5. 5
Platform Overview
Oral Immunotherapy - A Disruptive Technology
Disease
Specific
Antibodies
Induction
of
regulatory
T-cells
- Reduces systemic
inflammation
- Lowers organ injury
- Not associated with general
immune suppression
- No risks of severe infection
or malignancy
- Easily tolerated by patients
Vaccines Are
Developed
Antibodies Are
Harvested from
Colostrum
Bovine
adjuvants
IgG (IgG1)
Broad Therapeutic Effect
Clearance of
Targeted
Pathogens
1 2 3
+
+
Can create therapeutics targeting any microbiome signature(s)
Clinical supplies for new therapeutics can be ready for trials in as little as 6 months
Extended market protection (regulated as biologics)

6. Pipeline
Clinical Assets Targeting Blockbuster Indications
6
New trials since last update (Nov. 2015)
Pre-Clin Phase 1 Phase 2 Phase 3 Market
NASH
ASH
Pediatric NASH
IMM-529 Anti-Infective C-Difficile (Orphan)
IMM-124E
Anti-
Inflammatory
Colitis
TBD Anti-Infective US Army / Shigella
IMM-124E /
TBD
Microbiota Autism
Travelan /
Protectyn
OTC
Traveler's Diarrhea
/ Gut Dysbiosis
IMM-124E
Immuno-
Modulation
(NIH Trial)
(NIH Trial)

7. Dr Arun Sanyal (MD) – University of Virginia. Professor of Medicine and Former Chairman of the Division of
Gastroenterology, Hepatology and Nutrition, VCU Medical Center. Dr Sanyal is an internationally renowned expert in liver
diseases. He is a former President of the AASLD (American Association for the Study of Liver Diseases) and is the current
Chair of the Liver Study Section at the NIH.
Dr Stephen Harrison (MD) – Professor of Medicine, Uniformed Services University of the Health Sciences, Bethesda,
Maryland; Physician, San Antonio Military Medical Center, Fort Sam Houston, San Antonio, Texas. Chief of Residents, Internal
Medicine, Brooke US Army Medical Center. Dr. Harrison is an internationally renowned expert in NASH and his group has
published seminal work on many aspects in the field. Dr Harrison is the Principal Investigator of Galectin’s GR-MD-02’s Phase
II trial and hold's key roles in other leading clinical NASH studies.
Dr Manal Abdelmalek (MD) – Duke University Medical Center. Dr Abdelmalek is Associate Professor of Medicine at
Duke Medical University Medical Center, Division of Gastroenterology & Hepatology, Section of Hepatobiliary Diseases & Liver
Transplantation. Dr Abdelmalek is a leading investigator in the field of NASH.
Dr Gerhard Rogler (MD, PhD) – Zurich University. Dr Rogler is the Chairman of the Scientific Advisory Board of the
University of Zurich and Professor of Gastroenterology and Hepatology and Consultant Gastroenterologist at the Division of
Gastroenterology & Hepatology, Department of Medicine, Zürich University Hospital, Switzerland. Prof. Rogler is a leader in
the field of Colitis and has authored approximately 200 original peer-reviewed articles.
Dr Miriam Vos (MD) – Emory University. Dr Vos is an associate professor of pediatrics at the Emory University School of
Medicine, and an attending Hepatologist at Children’s Healthcare of Atlanta. She specializes in the treatment of
gastrointestinal disease in children as well as fatty liver disease and obesity. Dr. Vos is also the author of The No-Diet Obesity
Solution for Kids.
Dr. Dena Lyras (PhD) – Monash University. Dr Lyras is associate professor at Monash University, is one of the world’s
leading expert in C-Dfficile. Dr Lyras has spent her research career developing world-leading knowledge of C-Difficile. She
was the lead author of a seminal study published in Nature in 2009, which shed new light on the essential role specific toxins
play in causing disease, a discovery that disproved prevailing opinion.
Stellar KOL Support
Principal Investigators & Scientific Advisory Board
7

8. Immuron Limited
1H 2016 Developments
8
Company Overview and Pipeline
1H 2016 Developments
Upcoming Milestones
Summary

9. 9
1H2016 Developments
Clinical Assets – Fatty Liver Programs
NASH
50% recruitment milestones met in
NASH Phase 2 (May 2016)
1
Pediatric NASH
Initiation of Pediatric NASH study (3Q
2016)
2
Immuron’s NASH Portfolio:
(1) Phase 2 in NASH; (2) Phase in ASH and now (3) Phase 2 in
Pediatric NASH

10. 10
1H2016 Developments
Clinical Assets – C-Difficile
C-Difficile
IMM-529 reports highly successful
pre-clinical data (January 2016)
3
Strongly differentiated and unique triple action mechanism

11. 11
0 .0 0 .5 1 .0 1 .5 2 .0 2 .5 3 .0 3 .5 4 .0
0
2 0
4 0
6 0
8 0
1 0 0
S u rv iv a l
h o u rs p o s t in fe c tio n
Percentsurvival
U n in fe c te d , N o tre a tm e n t
In fe c te d , N o tre a tm e n t
In fe c te d , N o n -im m u n e Ig G tre a tm e n t
In fe c te d , IM M -5 2 9 tre a tm e n t
In fe c te d , V a n c o m y c in tre a tm e n t
0 1 2 3 4
0
2 0
4 0
6 0
8 0
1 0 0
D a y s p o s t in fe c tio n
Percentsurvival
S u rv iv a l
In fe c te d , N o tre a tm e n t
In fe c te d , N o n -im m u n e Ig G tre a tm e n t
In fe c te d , IM M -5 2 9 tre a tm e n t
In fe c te d , V a n c o m y c in tre a tm e n t
U n in fe c te d , N o tre a tm e n t
0 2 4 6 8 1 0 1 2 1 4 1 6 1 8 2 0
0
1 0
2 0
3 0
4 0
5 0
6 0
7 0
8 0
9 0
1 0 0
1 1 0
S u rv iv a l
D a y s a fte r v a n c o m y c in tre a tm e n t c e a s e d
Percentsurvival
In fe c te d + S O C
In fe c te d + S O C + IM M -5 2 9**
p=0.0027
IMM-529
Results of Pre-Clinical Study
All studies
statistically
significant
Demonstrated 80%
efficacy without use
of antibiotics
Demonstrated ~90%
survival rate vs. 22%
survival rate in control
group
Potentially only
therapeutic
(approved or in
development) that
can treat all phases
of the disease:
(1) Prophylaxis
(2) Treatment
(3) Recurrence
Demonstrated 80%
efficacy without use
of antibiotics
Prevention
Studies
Treatment
Studies
RelapseStudies

12. 12
IMM-529
Unique MOA in CDI
Heat, ethanol & UV
resistant. Survive gastric
acid, adhere to cells in the
colon & germinate
Spores – Infectious Particles
IMM-529 antibodies bind to
surface antigens on spores
& prevent adheres to host
cells & limit germination.
Vegetative Cells
Fimbriae & other surface
layer proteins (SLP)
contribute to bacterial
colonization. Fimbriae are
used to adhere to other
bacteria & to host cells
and isone of the primary
mechanisms of virulence
IMM-529 antibodies bind
to SLP on vegetative cells
& limit colonization.
Toxin B
IMM-529 antibodies
neutralise toxin B, inhibiting
toxin mediated epithelial
cell apoptosis & limit toxin
translocation into the
systemic circulation &
inflammatory cascades
Toxin B is essential for
virulence. Toxin B disrupt
the cytoskeleton and tight
junctions of intestinal
epithelial cells

13. 13
1H2016 Developments
Clinical Assets – Other
Colitis
Start of Pre-Clinical Programs
(February 2016)
4
Expansion and validation of Immuron’s Technology
Shigella
Vaccine
Collaboration with the US Army
(June 2016)
5
Autism
In collaboration with leading
Australian institutions (July 2016)
6

14. 14
1H2016 Developments
OTC Products
US Additions of multiple customers1
Expansion of retail and distribution footprint

15. 15
1H2016 Developments
OTC Products (continued)
US
Multiple PR Exposure (FOX, ABC,
NBC, etc.)
2
PR driving growing brand recognition in the US

16. 16
1H2016 Developments
OTC Products (continued)
China
Launch of Travelan and Protectyn in
China (June 2016)
3
Partnership with JD.com/QBID opens up direct-to-consumer e-
commerce channels

17. Immuron Limited
1H 2016 Developments
17
Company Overview and Pipeline
1H 2016 Developments
Upcoming Milestones
Summary

18. Key Milestones
Near Term and Long Term Milestones
18
Milestones Timing
OTC Products - Continued Expansion (New Territory and Sales Growth) Ongoing
C-DIFFICILE - Orphan Indication Filling 3Q2016
Pediatric NASH - Study Initiation 3Q2016
C-DIFFICILE - Manufacturing of Clinical Supplies Completed 3Q2016
C-DIFFICILE - Initiation of Phase 1 4Q2016
NASH - Interim Results 4Q2016
NASH - End of recruitment 4Q2016
C-DIFFICILE - Orphan Indication Granted 4Q2016
NASH - Top Line Phase II Mid-2017
COLITIS - Results of Pre-clinical Studies 2Q2017
C-DIFFICILE - Phase 1 Results 4Q2017
ASH - Top Line Phase 2 1H2018

19. Immuron Limited
1H 2016 Developments
19
Company Overview and Pipeline
1H 2016 Developments
Upcoming Milestones
Summary

20. Immuron Limited
Investment Highlights
• Strong Platform – Product already launched; NIH sponsored trials; Support
from leading KOLs
• Strong Pipeline with Significant Upside – Two Phase II clinical trials with
differentiated profiles in multi-billion market (Fatty liver disease - NASH/ASH)
- NASH: Phase II results - Mid-2017
- ASH: Phase II results - 2018; 100% funded by NIH
- Pediatric NASH
- C-difficile: Phase 1 results – Mid-2017
- US Army Collaboration
• Generating Growing Revenues from Marketed OTC Products – Targeting
WW $1.8M+ in 2016E; $3M-5M in 2017E; $30M/year peak revenues
• De-Risked Value Proposition – Significant upside from clinical assets,
coupled with growing revenues from OTC business
• Strong newsflow expected over the next 6-12 months
• Success in clinic could create licensing/M&A opportunity 20

21. THANK YOU